The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Myasthenia Gravis Disease-Global Market Insights and Sales Trends 2024
Synopsis
Myasthenia gravis (MG) is a long-term neuromuscular disease that leads to varying degrees of skeletal muscle weakness. The most commonly affected muscles are those of the eyes, face, and swallowing. It can result in double vision, drooping eyelids, trouble talking, and trouble walking. Onset can be sudden. Those affected often have a large thymus gland or develop a thymoma.
The global Myasthenia Gravis Disease market size is expected to reach US$ 1751.5 million by 2029, growing at a CAGR of 8.6% from 2023 to 2029. The market is mainly driven by the significant applications of Myasthenia Gravis Disease in various end use industries. The expanding demands from the Hospitals, Clinics and Academic Research Institutes,, are propelling Myasthenia Gravis Disease market. Medication, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Surgery segment is estimated at % CAGR for the next seven-year period.
Myasthenia gravis is generally treated with medications known as acetylcholinesterase inhibitors such as neostigmineand pyridostigmine. Immunosuppressants, such as prednisone or azathioprine, may also be used. The surgical removal of the thymus gland may improve symptoms in certain cases. Plasmapheresis and high dose intravenous immunoglobulin may be used during sudden flares of the condition. If the breathing muscles become significantly weak, mechanical ventilation may be required.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Myasthenia Gravis Disease, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Myasthenia Gravis Disease market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Myasthenia Gravis Disease market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Myasthenia Gravis Disease sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Myasthenia Gravis Disease covered in this report include Bausch Health, Sun Pharmaceuticals Industries, Novartis Pharmaceuticals, Teva Pharmaceutical Industries, Cipla, Roche, Apotex Corporation, Pfizer and Bristol-Myers And Company, etc.
The global Myasthenia Gravis Disease market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Bausch Health
Sun Pharmaceuticals Industries
Novartis Pharmaceuticals
Teva Pharmaceutical Industries
Cipla
Roche
Apotex Corporation
Pfizer
Bristol-Myers And Company
Global Myasthenia Gravis Disease market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Myasthenia Gravis Disease market, Segment by Type:
Medication
Surgery
Hematopoietic Stem Cell Transplantation (HSCT)
Other
Global Myasthenia Gravis Disease market, by Application
Hospitals
Clinics
Academic Research Institutes
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Myasthenia Gravis Disease companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Myasthenia gravis (MG) is a long-term neuromuscular disease that leads to varying degrees of skeletal muscle weakness. The most commonly affected muscles are those of the eyes, face, and swallowing. It can result in double vision, drooping eyelids, trouble talking, and trouble walking. Onset can be sudden. Those affected often have a large thymus gland or develop a thymoma.
The global Myasthenia Gravis Disease market size is expected to reach US$ 1751.5 million by 2029, growing at a CAGR of 8.6% from 2023 to 2029. The market is mainly driven by the significant applications of Myasthenia Gravis Disease in various end use industries. The expanding demands from the Hospitals, Clinics and Academic Research Institutes,, are propelling Myasthenia Gravis Disease market. Medication, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Surgery segment is estimated at % CAGR for the next seven-year period.
Myasthenia gravis is generally treated with medications known as acetylcholinesterase inhibitors such as neostigmineand pyridostigmine. Immunosuppressants, such as prednisone or azathioprine, may also be used. The surgical removal of the thymus gland may improve symptoms in certain cases. Plasmapheresis and high dose intravenous immunoglobulin may be used during sudden flares of the condition. If the breathing muscles become significantly weak, mechanical ventilation may be required.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Myasthenia Gravis Disease, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Myasthenia Gravis Disease market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Myasthenia Gravis Disease market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Myasthenia Gravis Disease sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Myasthenia Gravis Disease covered in this report include Bausch Health, Sun Pharmaceuticals Industries, Novartis Pharmaceuticals, Teva Pharmaceutical Industries, Cipla, Roche, Apotex Corporation, Pfizer and Bristol-Myers And Company, etc.
The global Myasthenia Gravis Disease market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Bausch Health
Sun Pharmaceuticals Industries
Novartis Pharmaceuticals
Teva Pharmaceutical Industries
Cipla
Roche
Apotex Corporation
Pfizer
Bristol-Myers And Company
Global Myasthenia Gravis Disease market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Myasthenia Gravis Disease market, Segment by Type:
Medication
Surgery
Hematopoietic Stem Cell Transplantation (HSCT)
Other
Global Myasthenia Gravis Disease market, by Application
Hospitals
Clinics
Academic Research Institutes
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Myasthenia Gravis Disease companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Myasthenia Gravis Disease
1.1 Myasthenia Gravis Disease Market Overview
1.1.1 Myasthenia Gravis Disease Product Scope
1.1.2 Myasthenia Gravis Disease Market Status and Outlook
1.2 Global Myasthenia Gravis Disease Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Myasthenia Gravis Disease Market Size by Region (2018-2029)
1.4 Global Myasthenia Gravis Disease Historic Market Size by Region (2018-2023)
1.5 Global Myasthenia Gravis Disease Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Myasthenia Gravis Disease Market Size (2018-2029)
1.6.1 North America Myasthenia Gravis Disease Market Size (2018-2029)
1.6.2 Europe Myasthenia Gravis Disease Market Size (2018-2029)
1.6.3 Asia-Pacific Myasthenia Gravis Disease Market Size (2018-2029)
1.6.4 Latin America Myasthenia Gravis Disease Market Size (2018-2029)
1.6.5 Middle East & Africa Myasthenia Gravis Disease Market Size (2018-2029)
2 Myasthenia Gravis Disease Market by Type
2.1 Introduction
2.1.1 Medication
2.1.2 Surgery
2.1.3 Hematopoietic Stem Cell Transplantation (HSCT)
2.1.4 Other
2.2 Global Myasthenia Gravis Disease Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Myasthenia Gravis Disease Historic Market Size by Type (2018-2023)
2.2.2 Global Myasthenia Gravis Disease Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Myasthenia Gravis Disease Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Myasthenia Gravis Disease Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Myasthenia Gravis Disease Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Myasthenia Gravis Disease Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Myasthenia Gravis Disease Revenue Breakdown by Type (2018-2029)
3 Myasthenia Gravis Disease Market Overview by Application
3.1 Introduction
3.1.1 Hospitals
3.1.2 Clinics
3.1.3 Academic Research Institutes
3.2 Global Myasthenia Gravis Disease Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Myasthenia Gravis Disease Historic Market Size by Application (2018-2023)
3.2.2 Global Myasthenia Gravis Disease Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Myasthenia Gravis Disease Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Myasthenia Gravis Disease Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Myasthenia Gravis Disease Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Myasthenia Gravis Disease Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Myasthenia Gravis Disease Revenue Breakdown by Application (2018-2029)
4 Myasthenia Gravis Disease Competition Analysis by Players
4.1 Global Myasthenia Gravis Disease Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Myasthenia Gravis Disease as of 2022)
4.3 Date of Key Players Enter into Myasthenia Gravis Disease Market
4.4 Global Top Players Myasthenia Gravis Disease Headquarters and Area Served
4.5 Key Players Myasthenia Gravis Disease Product Solution and Service
4.6 Competitive Status
4.6.1 Myasthenia Gravis Disease Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Bausch Health
5.1.1 Bausch Health Profile
5.1.2 Bausch Health Main Business
5.1.3 Bausch Health Myasthenia Gravis Disease Products, Services and Solutions
5.1.4 Bausch Health Myasthenia Gravis Disease Revenue (US$ Million) & (2018-2023)
5.1.5 Bausch Health Recent Developments
5.2 Sun Pharmaceuticals Industries
5.2.1 Sun Pharmaceuticals Industries Profile
5.2.2 Sun Pharmaceuticals Industries Main Business
5.2.3 Sun Pharmaceuticals Industries Myasthenia Gravis Disease Products, Services and Solutions
5.2.4 Sun Pharmaceuticals Industries Myasthenia Gravis Disease Revenue (US$ Million) & (2018-2023)
5.2.5 Sun Pharmaceuticals Industries Recent Developments
5.3 Novartis Pharmaceuticals
5.3.1 Novartis Pharmaceuticals Profile
5.3.2 Novartis Pharmaceuticals Main Business
5.3.3 Novartis Pharmaceuticals Myasthenia Gravis Disease Products, Services and Solutions
5.3.4 Novartis Pharmaceuticals Myasthenia Gravis Disease Revenue (US$ Million) & (2018-2023)
5.3.5 Teva Pharmaceutical Industries Recent Developments
5.4 Teva Pharmaceutical Industries
5.4.1 Teva Pharmaceutical Industries Profile
5.4.2 Teva Pharmaceutical Industries Main Business
5.4.3 Teva Pharmaceutical Industries Myasthenia Gravis Disease Products, Services and Solutions
5.4.4 Teva Pharmaceutical Industries Myasthenia Gravis Disease Revenue (US$ Million) & (2018-2023)
5.4.5 Teva Pharmaceutical Industries Recent Developments
5.5 Cipla
5.5.1 Cipla Profile
5.5.2 Cipla Main Business
5.5.3 Cipla Myasthenia Gravis Disease Products, Services and Solutions
5.5.4 Cipla Myasthenia Gravis Disease Revenue (US$ Million) & (2018-2023)
5.5.5 Cipla Recent Developments
5.6 Roche
5.6.1 Roche Profile
5.6.2 Roche Main Business
5.6.3 Roche Myasthenia Gravis Disease Products, Services and Solutions
5.6.4 Roche Myasthenia Gravis Disease Revenue (US$ Million) & (2018-2023)
5.6.5 Roche Recent Developments
5.7 Apotex Corporation
5.7.1 Apotex Corporation Profile
5.7.2 Apotex Corporation Main Business
5.7.3 Apotex Corporation Myasthenia Gravis Disease Products, Services and Solutions
5.7.4 Apotex Corporation Myasthenia Gravis Disease Revenue (US$ Million) & (2018-2023)
5.7.5 Apotex Corporation Recent Developments
5.8 Pfizer
5.8.1 Pfizer Profile
5.8.2 Pfizer Main Business
5.8.3 Pfizer Myasthenia Gravis Disease Products, Services and Solutions
5.8.4 Pfizer Myasthenia Gravis Disease Revenue (US$ Million) & (2018-2023)
5.8.5 Pfizer Recent Developments
5.9 Bristol-Myers And Company
5.9.1 Bristol-Myers And Company Profile
5.9.2 Bristol-Myers And Company Main Business
5.9.3 Bristol-Myers And Company Myasthenia Gravis Disease Products, Services and Solutions
5.9.4 Bristol-Myers And Company Myasthenia Gravis Disease Revenue (US$ Million) & (2018-2023)
5.9.5 Bristol-Myers And Company Recent Developments
6 North America
6.1 North America Myasthenia Gravis Disease Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Myasthenia Gravis Disease Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Myasthenia Gravis Disease Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Myasthenia Gravis Disease Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Myasthenia Gravis Disease Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Myasthenia Gravis Disease Market Dynamics
11.1 Myasthenia Gravis Disease Industry Trends
11.2 Myasthenia Gravis Disease Market Drivers
11.3 Myasthenia Gravis Disease Market Challenges
11.4 Myasthenia Gravis Disease Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
